Clinical Trial Update: To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety and efficacy of HSK16149 in Chinese patients with peripheral neuropathic pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Neuropathic Pain

Drugs mentioned

• HSK16149

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Peripheral Neuropathic Pain | Phase 3 | Status: COMPLETED